In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

D. Medical Industries, Ltd.

http://dmedicalindustries.com/

Latest From D. Medical Industries, Ltd.

US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?

Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.

Sales & Earnings Dietary Supplements

Bayer Extends Afrin Line With First OTC Oxymetazoline Spray In US For Children Under 6

Children’s Afrin regular and no-drip formulations reach US stores with consumers having choices between dozens of oxymetazoline nasal sprays available under an FDA OTC monograph. But products indicated for children was limited to one, Mucinex Childrens Stuffy Nose, and it’s for children 6 and up.

OTC Drugs Launches

Church & Dwight Delays Expanding VMS Production Capacity As Pandemic-Driven Sales Growth Slows

Sales of Waterpik oral care devices and Flawless feminine hair-removal, skin and nail care line also slowed during Q3. Those two and vitamin business combined for 6% drag on net sales, finishing flat at $1.32bn.

Consumer Sales & Earnings

US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?

Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.

Sales & Earnings OTC Drugs
See All

Company Information

  • Industry
  • Biotechnology
  • Miscellaneous
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • In Vitro Diagnostics
    • Glucose Testing
  • Other Names / Subsidiaries
    • D-Medical
UsernamePublicRestriction

Register